On the safety of biological drugs and targeted therapies in rheumatology

Abstract

With the advent of biological drugs in Rheumatology, more than 20 years ago, a new chapter in the treatment of rheumatic diseases was inaugurated, with notable improvements in the quality of life of patients reflected through sustained remissions, decrease in structural progression, significant reduction in the evolution to disability, being that many patients today can lead a normal life even in conditions of basally aggressive diseases. Fifteen years later, with the advent of JAK inhibitors, therapeutics expanded the opportunities for oral treatments with high efficacy rates. However, like any medicine with immunomodulatory action, all these treatments are not exempt from adverse effects, some of them frequent and expected, others more rare and with different levels of intensity.